Clinical Research Directory

Inclusion Criteria: * Pathological evidence of newly diagnosed glioblastoma according to WHO classification criteria * Patients 18 to 70 years of age with a WHO performance status of 2 or less * All patients must sign written informed consent * Adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥1,5 x 103/μL; platelet count, ≥100 x 103/μL; serum creatinine ≤1.7 mg/dL; total bilirubin \> upper limit of normal; AST or ALT ≤3 times the upper limit of normal) * Patient must have received subtotal or gross total resection of the tumor * MGMT-promotor methylated patients must have refused therapy according to the CeTeG/NOA-09 protocol (+ Lomustin) * Patient must be planned for concomitant RCT with a total RT dose of 60 Gy over six weeks and temozolomide followed by six cycles of maintenance CT using temozolomide Exclusion Criteria: * Previous cranial RT * Cytostatic therapy / anti-angiogenic substances / CT or radiation therapy for cancer within the past 5 years * History of cancers or other comorbidities that limit life expectancy to less than five years * Postoperative evidence of increased intracranial pressure (midline shift \> 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness) * Technical impossibility to use magnetic resonance imaging (MRI) or known allergies against MRI and/or computed tomography (CT) contrast agents * Technical impossibility to use AM-RF-EMF (pacemaker, defibrillator or deep brain stimulator, metal implants) * Participants of childbearing age unwilling to use or not capable of using effective contraception * Pregnant patients